On Wednesday, Guardant Health (GH) stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.
↑ XThis exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an 80 or higher RS Rating as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Guardant Health stock is trying to complete a cup without handle with a 37.04 entry. See if the medical stock can break out in heavy volume. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The precision oncology company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 34%.
Guardant Health stock holds the No. 9 rank among its peers in the Medical-Services industry group. Hims & Hers Health (HIMS), Castle Biosciences (CSTL) and Quest Diagnostics (DGX) are among the top 5 highly rated stocks within the group.
YOU MAY ALSO LIKE:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。